6pm: https://globalmeet.webcasts.com/starthere.jsp?ei=1726339&tp_key=a74808d75e
8pm: https://globalmeet.webcasts.com/starthere.jsp?ei=1726340&tp_key=c976e0450a
Program Description
The introduction of targeted therapies, including small molecule inhibitors targeting BTK and BCL-2, has improved survival outcomes in patients with chronic lymphocytic leukemia (CLL). However, these therapies can also cause class-specific and agent-specific toxicities, impacting adherence. This session will provide a comprehensive overview of CLL and its evolving treatment landscape, focusing on recent updates in treatment guidelines and clinical trial data. Current first- and second-line treatment approaches will be discussed, with an emphasis on treatment selection beyond age and comorbidities with a focus on del(17p)/TP53 mutation status, the continued role of ibrutinib-based regimens, and continuous versus fixed-duration treatment. As oncology pharmacists play a crucial role in collaborating with oncologists to optimize therapy selection, the session will also delve into multidisciplinary strategies to ensure the safety of small molecule inhibitors, including monitoring for and managing cardiac toxicities. Oncology pharmacists will explore strategies for managing BTK inhibitor intolerance and resistance, best practices for toxicity management, and treatment options for patients refractory to first-line therapies, emphasizing opportunities for shared decision-making.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: August 12, 2025
Expiration date: October 12, 2025
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Manage frontline treatment plans for patients with chronic lymphocytic leukemia (CLL) by incorporating patient- and disease-specific considerations.
- Identify optimized therapeutic sequencing strategies for second-line and subsequent CLL therapies.
- Apply effective strategies to monitor and manage toxicities of targeted therapies in CLL.
Karen M. Fancher, PharmD, BCOP
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist – Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, PA
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-224-L01-P. The activity is available for CE credit through October 12, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Karen M. Fancher, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms